Related Tags >> Vivus obesity biopharmaceutical company Type 2 Diabetes

Qnexa News

Most Popular Qnexa Story

Three biotechs race for Holy Grail of drug development

October 19, 2009 — 7:11am ET | By John Carroll

One of the most closely watched competitions in biotechnology involves the final sprint toward marketing approval by Orexigen Therapeutics, Vivus and Arena Pharmaceuticals, each of which is at work Read more...

Qnexa Press Releases

15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
The Obesity Drug Market Will Increase More Than Six-Fold over the Next Decade, Increasing to $2.6 Billion in 2020 in the U
VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
VIVUS Provides Regulatory Update on QNEXA NDA

Latest Headlines

Vivus buoyed by FDA's willingness to drop Qnexa restriction
January 9, 2012
UPDATED: Vivus sinks after delivering oral cleft data on obesity drug ingredient
December 22, 2011
FDA gives new shot to Vivus obesity drug
November 4, 2011
Vivus gets back in the race for weight-loss drug OK, resubmits Qnexa
October 17, 2011
Vivus shares buoyed as FDA allows early resubmission on Qnexa
September 15, 2011
Epilepsy study results could help Vivus' Qnexa
May 20, 2011
Vivus eyes path to a limited approval for obesity drug
May 3, 2011
Vivus surges on fresh batch of promising obesity drug data
April 4, 2011
FDA wants birth defect data from Vivus ($VVUS)
January 21, 2011
FDA hands Vivus a complete response letter for Qnexa
October 28, 2010
After FDA's ARNA decision, what's next for obesity drugs?
October 25, 2010
Qnexa - FDA's Top 10 Blockbuster Decisions
October 11, 2010
Vivus offers upbeat assessment of two-year Qnexa data
September 21, 2010
Did the odds just get worse for Arena's new weight drug?
August 9, 2010
Orexigen weight-loss drug shows positive results in study
July 30, 2010
Expert panel not convinced by Vivus' Qnexa
July 15, 2010
Vivus' Qnexa takes center stage during panel review
July 15, 2010
Vivus shares rally after FDA staffers detail Qnexa concerns
July 13, 2010
Spotlight shifts to Vivus' Qnexa
July 12, 2010
FDA panel to review Vivus drug in July
March 26, 2010

Paid Research Reports

More Research Reports >>